Меню
Идёт набор NCT06541158

Transportation for Cancer Care Navigation Tool for Reducing Travel Barriers Among Patients With Solid Tumors Receiving Radiation Therapy

Без фазы С лечением Malignant Solid Neoplasm

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Best Practice, Discussion, Educational Intervention, Health Promotion and Care.
Кому может быть актуально
Состояния в реестре: Malignant Solid Neoplasm. Базовые параметры: от 18 лет · Все.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
США
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

Testing the Feasibility of a Transportation for Cancer Care Navigation Tool (TRACT) in Solid Tumors Patients Receiving Radiotherapy

Обзор

This clinical trial evaluates whether the Transportation for Cancer Care Navigation Tool (TRACT) can reduce travel barriers among patients with solid tumors receiving radiation therapy. It is estimated that 20-30% patients with cancer experience travel-related barriers for cancer care. This is a particular problem for patients with radiation therapy as these patients frequently receive multiple treatment cycles, which often require daily treatment for multiple weeks or months. Addressing travel barriers has been a prerequisite for cancer care as travel barriers negatively influence cancer treatment adherence and cancer care outcomes, such as survival and quality of life. The TRACT program may help reduce travel barriers and therefore promote health equity among patients with solid tumors receiving radiation therapy.

Подробное описание

PRIMARY OBJECTIVES:

I. To work collaboratively with a Community Advisory Board (CAB, e.g., patients, caregivers, clinicians, and social workers) to refine a theory-driven TRACT program for solid tumor patients receiving radiation therapy (RT) with travel barriers.

II. To evaluate the feasibility of the TRACT program for patients with solid tumors receiving RT with travel barriers.

III. To explore the efficacy of the TRACT program on RT adherence (canceling, delaying, missing, or terminating essential care) and patient-reported outcomes (PROs) (distress, financial toxicity, and quality of life \[QOL\]) compared to enhanced usual care (EUC, usual care + transportation awareness brief video with Patient Advocate Foundation \[PAF\] pamphlet).

OUTLINE:

STAGE I (CAB): Participants meet with the study research team to develop and refine the TRACT program.

STAGE II: Patients are randomized to 2 groups.

GROUP I: Patients receive the TRACT program consisting: of 1) Screening of travel barriers; 2) Awareness of transportation obstacles and resources using videos, 3) Assistance with transportation resource application and utilization, and 4) Alignment of community resources to navigate individualized transportation support by the trained travel navigator for 3 months.

GROUP II: Patients receive usual care with PAF pamphlet for 3 months.

After completion of study intervention, patients are followed up at 3 months.

Вмешательства

  • Другое Best Practice
    Receive usual care
  • Другое Discussion
    Participate in a CAB
  • Другое Educational Intervention
    Receive PAF pamphlet
  • Поведенческое Health Promotion and Care
    Receive the TRACT program
  • Другое Media Intervention
    Receive transportation awareness brief video
  • Другое Questionnaire Administration
    Ancillary studies

Первичные конечные точки

  • Feasibility of screening patients for the Transportation for Cancer Care Navigation Tool (TRACT) program [Срок оценки: At T0 (pre-intervention) and T1 (3 months post-intervention)]
  • Recruitment to the TRACT program (Feasibility) [Срок оценки: At T0 (pre-intervention) and T1 (3 months post-intervention)]
  • Retention and adherence rate (Feasibility) [Срок оценки: At T0 (pre-intervention) and T1 (3 months post-intervention)]
  • Acceptability of the Transportation for Cancer Care Navigation Tool [Срок оценки: At T0 (pre-intervention) and T1 (3 months post-intervention)]
  • Travel barriers [Срок оценки: At T0 (3 months) and T1 (3 months post-intervention)]
  • Treatment adherence [Срок оценки: At T1 (3 months post-intervention)]
  • Distress [Срок оценки: At T0 (3 months) and T1 (3 months post-intervention)]
  • Financial toxicity [Срок оценки: At T0 (3 months) and T1 (3 months post-intervention)]
  • Quality of life (QOL) [Срок оценки: At T0 (3 months) and T1 (3 months post-intervention)]

Критерии участия

Критерии включения

  • Age ≥ 18 years
  • Diagnosed with solid tumors
  • Undergoing RT (not excluded with chemotherapy)
  • Competent to give consent
  • English-speaking
  • With travel barriers as screened by the reliable and validated 10-item Transportation Barriers Measure. In this study, item 2 ("how much trouble is it for you to get transportation to your doctor or treatment?") from the general barriers domain will be used to screen patients for travel barriers

Критерии исключения

  • Receive palliative care
  • Are non-English-speaking (excluded due to pilot data without fund to support translation services)
  • Are enrolled in lodging programs (e.g., the American Cancer Society \[ACS\] Hope Lodge®)
  • Have major depression/anxiety disorders that interfere with their ability to participate (based on the electronic medical records report)

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Рандомизированное
Модель
Параллельные группы
Маскирование
Открытое
Основная цель
Поддерживающая терапия

Центры проведения

США · 4 центра
  • Emory Proton Therapy Center — Atlanta
  • Emory University Hospital Midtown — Atlanta
  • Emory University Hospital/Winship Cancer Institute — Atlanta
  • Emory Saint Joseph's Hospital — Atlanta

Идентификаторы

NCT: NCT06541158 · STUDY00007528 · NCI-2024-05756 · STUDY00007528 · WINSHIP6207-24 · P30CA138292

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗